No data are available on the extent of systemic absorption from TOBRADEX® (tobramycin and dexamethasone ophthalmic suspension); however, it is known that some systemic absorption can occur with ocularly applied drugs. If the maximum dose of TOBRADEX® (tobramycin and dexamethasone ophthalmic suspension) is given for the first 48 hours (two drops in each eye every 2 hours) and complete systemic absorption occurs, which is highly unlikely, the daily dose of dexamethasone would be mg. The usual physiologic replacement dose is mg daily. If TOBRADEX® (tobramycin and dexamethasone ophthalmic suspension) is given after the first 48 hours as two drops in each eye every 4 hours, the administered dose of dexamethasone would be mg daily.
The following adverse reactions are classified according to the following convention: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1000), very rare (<1/10,000) or not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in decreasing order of seriousness. The adverse reactions were obtained from clinical trials and post-marketing experience for MAXITROL eye drops and MAXITROL eye ointment.
Steroid and antibiotic eye drops - hydrocortisone/neomycin/polymixin B; loteprednol/tobramycin; prednisolone/gentamycin; prednisolone/sulfacetamide; hydrocortisone /neomycin/bacitracin/ polymyxin B (Blephamide, Catapred [discontinued], Isopto, Pred-G, Poly-Pred [discontinued], Tobradex, Zylet and many other brands) are steroid and antibiotic eye drops prescribed to prevent or treat eye infections that are associated with inflammation. Side effects, drug interactions, dosage, and pregnancy safety information should be reviewed prior to using these medications.